Karin Schmelz

1.7k total citations
22 papers, 927 citations indexed

About

Karin Schmelz is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Karin Schmelz has authored 22 papers receiving a total of 927 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 7 papers in Oncology and 7 papers in Hematology. Recurrent topics in Karin Schmelz's work include Acute Myeloid Leukemia Research (7 papers), Cell death mechanisms and regulation (7 papers) and Epigenetics and DNA Methylation (6 papers). Karin Schmelz is often cited by papers focused on Acute Myeloid Leukemia Research (7 papers), Cell death mechanisms and regulation (7 papers) and Epigenetics and DNA Methylation (6 papers). Karin Schmelz collaborates with scholars based in Germany, Austria and Switzerland. Karin Schmelz's co-authors include Bernd Dörken, Ingo Tamm, Mandy Wagner, Frank Eßmann, Klaus Schulze‐Osthoff, Thomas Wieder, Aram Prokop, Rudi Beyaert, Peter T. Daniel and Rainer Cramm and has published in prestigious journals such as Blood, Oncogene and Molecular Microbiology.

In The Last Decade

Karin Schmelz

21 papers receiving 909 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Karin Schmelz Germany 13 727 244 145 106 104 22 927
Jaira F. de Vasconcellos United States 14 549 0.8× 136 0.6× 125 0.9× 162 1.5× 167 1.6× 33 910
Yuhui Liu China 10 496 0.7× 232 1.0× 186 1.3× 115 1.1× 151 1.5× 18 811
Efstratios Katsoulidis United States 20 779 1.1× 283 1.2× 244 1.7× 269 2.5× 119 1.1× 21 1.2k
LJ Fairbairn United Kingdom 17 566 0.8× 295 1.2× 207 1.4× 257 2.4× 107 1.0× 32 1.0k
María José Muñoz-Alonso Spain 15 604 0.8× 262 1.1× 75 0.5× 65 0.6× 113 1.1× 22 840
Anna R. Poetsch Germany 14 742 1.0× 137 0.6× 100 0.7× 59 0.6× 104 1.0× 25 991
Jie Zha China 14 454 0.6× 142 0.6× 142 1.0× 134 1.3× 199 1.9× 50 760
Yiqing Chi United States 13 555 0.8× 103 0.4× 280 1.9× 137 1.3× 139 1.3× 16 933
Weiping Luo United States 18 543 0.7× 242 1.0× 64 0.4× 200 1.9× 117 1.1× 44 1.2k

Countries citing papers authored by Karin Schmelz

Since Specialization
Citations

This map shows the geographic impact of Karin Schmelz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karin Schmelz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karin Schmelz more than expected).

Fields of papers citing papers by Karin Schmelz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karin Schmelz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karin Schmelz. The network helps show where Karin Schmelz may publish in the future.

Co-authorship network of co-authors of Karin Schmelz

This figure shows the co-authorship network connecting the top 25 collaborators of Karin Schmelz. A scholar is included among the top collaborators of Karin Schmelz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karin Schmelz. Karin Schmelz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Szymansky, Annabell, Kathy Astrahantseff, Carolina Rosswog, et al.. (2025). Serially Quantifying TERT Rearrangement Breakpoints in ctDNA Enables Minimal Residual Disease Monitoring in Patients with Neuroblastoma. Cancer Research Communications. 5(1). 167–177.
2.
Retter, Ida, et al.. (2024). 3R centres contributions to change animal experimentation. EMBO Reports. 25(10). 4105–4109. 2 indexed citations
3.
Carlet, Michela, Karin Schmelz, Tobias Herold, et al.. (2022). X‐linked inhibitor of apoptosis protein represents a promising therapeutic target for relapsed/refractory ALL. EMBO Molecular Medicine. 15(1). e14557–e14557. 5 indexed citations
4.
Sprüssel, Annika, Kathy Astrahantseff, Karin Schmelz, et al.. (2020). Multiplexed Quantification of Four Neuroblastoma DNA Targets in a Single Droplet Digital PCR Reaction. Journal of Molecular Diagnostics. 22(11). 1309–1323. 11 indexed citations
5.
Schmelz, Karin, Jutta Proba, Annika Winkler, et al.. (2017). Reactivating TP53 signaling by the novel MDM2 inhibitor DS-3032b as a therapeutic option for high-risk neuroblastoma. Oncotarget. 9(2). 2304–2319. 65 indexed citations
6.
Hundsdoerfer, Patrick, et al.. (2010). XIAP expression is post‐transcriptionally upregulated in childhood ALL and is associated with glucocorticoid response in T‐cell ALL. Pediatric Blood & Cancer. 55(2). 260–266. 40 indexed citations
7.
Wagner, Mandy, Karin Schmelz, Bernd Dörken, & Ingo Tamm. (2008). Epigenetic and genetic analysis of the survivin promoter in acute myeloid leukemia. Leukemia Research. 32(7). 1054–1060. 36 indexed citations
8.
Demuth, Ilja, Paul S. Bradshaw, Julia Kallenbach, et al.. (2008). Endogenous hSNM1B/Apollo interacts with TRF2 and stimulates ATM in response to ionizing radiation. DNA repair. 7(8). 1192–1201. 28 indexed citations
9.
Wagner, Mandy, Karin Schmelz, Bernd Dörken, & Ingo Tamm. (2007). Transcriptional regulation of human survivin by early growth response (Egr)‐1 transcription factor. International Journal of Cancer. 122(6). 1278–1287. 22 indexed citations
10.
Demuth, Ilja, Karin Schmelz, Karl Sperling, et al.. (2007). Extreme variation in apoptosis capacity amongst lymphoid cells of Nijmegen breakage syndrome patients. European Journal of Cell Biology. 87(2). 111–121. 7 indexed citations
11.
Wagner, Mandy, Karin Schmelz, Christian Wuchter, et al.. (2006). In vivo expression of survivin and its splice variant survivin‐2B: Impact on clinical outcome in acute myeloid leukemia. International Journal of Cancer. 119(6). 1291–1297. 47 indexed citations
12.
Tamm, Ingo, Karin Schmelz, Bernd Dörken, & Mandy Wagner. (2006). Survivin Is Negatively Regulated by Early Growth Response (Egr)-1 Transcription Factor in Acute Myeloid Leukemia.. Blood. 108(11). 1943–1943. 3 indexed citations
13.
Tamm, Ingo, Mandy Wagner, & Karin Schmelz. (2005). Decitabine activates specific caspases downstream of p73 in myeloid leukemia. Annals of Hematology. 84(S1). 47–53. 20 indexed citations
14.
Tamm, Ingo, et al.. (2005). Decitabine: Where Is the Target?.. Blood. 106(11). 495–495. 3 indexed citations
15.
16.
Schmelz, Karin, Thomas Wieder, Ingo Tamm, et al.. (2004). Tumor necrosis factor α sensitizes malignant cells to chemotherapeutic drugs via the mitochondrial apoptosis pathway independently of caspase-8 and NF-κB. Oncogene. 23(40). 6743–6759. 31 indexed citations
17.
Schmelz, Karin, Mandy Wagner, Bernd Dörken, & Ingo Tamm. (2004). 5‐Aza‐2′‐deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53‐independent apoptosis in myeloid leukemia. International Journal of Cancer. 114(5). 683–695. 98 indexed citations
18.
Tamm, Ingo, Stephan Richter, Frank Scholz, et al.. (2004). XIAP expression correlates with monocytic differentiation in adult de novo AML: impact on prognosis. The Hematology Journal. 5(6). 489–495. 82 indexed citations
19.
Tamm, Ingo, Mandy Wagner, Bernd Dörken, & Karin Schmelz. (2004). 5′-AZA-2′-Deoxycytidine Induces p21/WAF Expression by Demethylation of p73 Leading to p53-Independent Apoptosis in Myeloid Leukemia.. Blood. 104(11). 1166–1166. 7 indexed citations
20.
Pohlmann, Anne, et al.. (2000). A novel NO‐responding regulator controls the reduction of nitric oxide in Ralstonia eutropha. Molecular Microbiology. 38(3). 626–638. 89 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jaira F. de Vasconcellos Breakdown of academic impact, for papers by Yuhui Liu Breakdown of academic impact, for papers by Efstratios Katsoulidis Breakdown of academic impact, for papers by LJ Fairbairn Breakdown of academic impact, for papers by María José Muñoz-Alonso Breakdown of academic impact, for papers by Anna R. Poetsch Breakdown of academic impact, for papers by Jie Zha Breakdown of academic impact, for papers by Yiqing Chi Breakdown of academic impact, for papers by Weiping Luo
Rankless by CCL
2026